Josep Tabernero, M.D., Ph.D.

Dr. Tabernero is currently the Head of the Medical Oncology Department at the Vall d’Hebron Barcelona Hospital Campus and Director of the Vall d’Hebron Institute of Oncology (VHIO). He also co-directs the VHIO´s Gastrointestinal and Endocrine Tumours Group and the Research Unit for Molecular Therapy of Cancer (UITM) and is Principal Investigator of several Phase 1 pharmacodynamic studies and translational projects with molecular targeted therapies, as well as Phase 2 and 3 studies with novel chemotherapeutics. His group aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation. One of his team´s main objectives is to establish novel predictive markers of response to anti-cancer therapies and identify markers of primary resistance (de novo) and secondary treatment. Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery and Clinical Cancer Research. He has authored or co-authored approximately 550 peer-reviewed papers. He has served as President of the European Society for Medical Oncology (ESMO) during the 2018 – 2019 term. He is also member of the AACR and ASCO, and has been appointed as member of several Educational and Scientific Committees of ESMO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and ESMO-GI/WCGIC meetings.